Sahajanand Medical Technologies (SMT) announced that the FIRE trial showed sustained safety and efficacy of its Supraflex Cruz drug-eluting stent in elderly patients with myocardial infarction and multivessel disease. Results were presented at the European Society of Cardiology (ESC) Congress 2025. The randomized study enrolled 1,445 patients … [Read more...] about SMT reports positive 3-year results from Supraflex Cruz stent trial
Sahajanand Medical Technologies
SMT receives France national reimbursement for heart stent
Sahajanand Medical Technologies recently received full reimbursement confirmation in France for its Supraflex Cruz heart stent. The Ministry of Health and Public Affairs of France conducted a scientific review for reimbursement. The clinical data the heart stent was evaluated for safety and applicability to France's population. Reimbursement … [Read more...] about SMT receives France national reimbursement for heart stent
